Clinical trials: Tumor Immunity
ALL, AML
Photochemotherapy and Graft-versus-leukemia in Acute-leukemia
Cure of leukemia after hematopoietic stem cell transplantation (HSCT) is sustained by the anti-leukemic effect of the grafted cells (graft-versus-leukemia (GVL)).
- Conditions
- ALL, AML, Acute GVHD, Tumor Immunity
- Trial name
- NCT02631993
- Testing
- Photochemotherapy
- Where
- Sweden
- Volunteers
- 47 people
- Sponsor
- Karolinska University Hospital
Colon Cancer
OMega-3 Fatty Acid for the Immune Modulation of Colorectal Cancer
This is a prospective, double-blind, placebo-controlled, randomized clinical trial to assess the effects of daily 4-gram marine omega-3 polyunsaturated fatty acid (MO3PUFA), through treatment with AMR101 (VASCEPA, icosapent…
- Trial name
- OMICC (NCT03661047)
- Testing
- AMR101 (VASCEPA, icosapent ethyl)
- Where
- United States
- Sponsor
- Massachusetts General Hospital
Acute Myeloid Leukemia, Myeloid Leukemia
Anti-Leukemia Immune Responses After Irradiation of Extramedullary Tumors
This clinical trial assesses how the immune system responds to leukemia tumors after low dose radiation delivered as part of standard of care.
- Conditions
- Acute Myeloid Leukemia, Myeloid Leukemia, Recurrent Acute Myeloid Leukemia
- Trial name
- NCT05035706
- Testing
- Biopsy, Biospecimen Collection, Electronic Health Record Review
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- M.D. Anderson Cancer Center
Accelerated Phase CML, BCR-ABL1 Positive, Acute Lymphoblastic Leukemia in Remission
CMV-MVA Triplex Vaccination of Stem Cell Donors in Preventing CMV Viremia in Participants With Allogeneic Transplant
This phase II trial studies how well multi-peptide CMV-modified vaccinia Ankara (CMV-MVA Triplex) vaccination of stem cell donors works in preventing cytomegalovirus (CMV) viremia in participants with blood cancer undergoing…
- Conditions
- Accelerated Phase CML, BCR-ABL1 Positive, Acute Lymphoblastic Leukemia in Remission, Acute Myeloid Leukemia in Remission, Chronic Lymphocytic Leukemia
- Trial name
- NCT03560752
- Testing
- Multi-peptide CMV-Modified Vaccinia Ankara Vaccine
- Where
- United States
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- City of Hope Medical Center
Breast Cancer, Triple Negative Breast Cancer
Effect of Pembrolizumab (Keytruda®) on Biomarkers in Early Breast Cancer.
The study consists of 2 parts: a retrospective study, and a prospective clinical study with pembrolizumab (Keytruda®) (Phase 0). 1.
- Conditions
- Breast Cancer, Triple Negative Breast Cancer, Hormone Receptor Negative Neoplasm
- Trial name
- NCT03197389
- Testing
- Pembrolizumab
- Where
- Belgium
- Volunteers
- 54 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Localized Cancer
Neo-adjuvant Immunotherapy Master Trial for Localized Cancers
Most cancer treatments are developed without knowing whether the drug's targets are actually present in a patient's tumor or whether the patient is likely to benefit from the treatment.
- Trial name
- NEOREM (NCT07262489)
- Testing
- Each therapeutic NEOREM sub-protocol will mention the description of intervention
- Where
- France
- Volunteers
- 200 people
- Sponsor
- UNICANCER
COVID-19, Cancer
SARS-CoV-2 Specific Immune Response After COVID-19 Vaccination in Cancer Patients
Our study highlights a low degree of neutralization-afforded protection mounted by CoronaVac in cancer patients when compared with healthy volunteers, especially patients who received chemotherapy.
- Trial name
- NCT05313074
- Testing
- CoronaVac vaccine
- Where
- Thailand
- Volunteers
- 311 people, healthy volunteers welcome
- Sponsor
- National Cancer Institute, Thailand
EBV, Epstein-Barr Virus Infection
Epstein-Barr Virus (EBV) gH/gL/gp42-Ferritin Nanoparticle Vaccine With or Without gp350-Ferritin in Healthy Adults With or Without EBV Infection
Background: Epstein-Barr virus (EBV) is the primary cause of infectious mononucleosis, commonly known as mono. EBV infects more than 90% of the world s population.
- Conditions
- EBV, Epstein-Barr Virus Infection, Infectious Mononucleosis, Mono
- Trial name
- NCT06908096
- Testing
- EBV gp350-ferritin vaccine with ALFQ adjuvant, EBV gH/gL/gp42-ferritin nanoparticle vaccine with ALFQ adjuvant
- Where
- United States
- Volunteers
- 750 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Melanoma
Safety Study of Adjuvant Vaccine to Treat Melanoma Patients
The incidence of melanoma is increasing with an estimated incidence of 59,940 cases and an annual death rate of 8110 in 2007. Although patients diagnosed with early stage disease have an excellent clinical outcome, patients…
- Trial name
- NCT01079741
- Testing
- NY-ESO-1 protein; Poly-ICLC; Montanide
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- Nina Bhardwaj
Anaplastic Astrocytoma, Anaplastic Oligoastrocytoma
Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors
This phase I trial studies the side effects and best schedule of vaccine therapy with or without sirolimus in treating patients with cancer-testis antigen (NY-ESO-1) expressing solid tumors.
- Conditions
- Anaplastic Astrocytoma, Anaplastic Oligoastrocytoma, Anaplastic Oligodendroglioma, Estrogen Receptor Negative
- Trial name
- NCT01522820
- Testing
- DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Laboratory Biomarker Analysis, Pharmacological Study
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Roswell Park Cancer Institute
Colon Cancer
Effect of Omega-3 Fatty Acids on the Perioperative Immune Response and Erythrocyte Function
Ideally, the postoperative inflammatory response is part of a well-orchestrated mechanism that contributes to tissue healing and rapid recovery.
- Trial name
- EMPIRE (NCT02231203)
- Testing
- Omegaven
- Where
- Netherlands
- Volunteers
- 44 people
- Sponsor
- Medical Center Alkmaar
Breast Cancer, Endocrine Therapy
Relationship Between Body Composition, Food Consumption, and Micro and Macronutrients With Gene Expression in Breast Cancer
The protocol involves measurement of 25 hidroxy vitamin D, gene expression of cytochrome and vitamin D receptor , endoxifen, tamoxifen, exemestane, and other metobolites related to nutrition and endocrine metabolism.
- Conditions
- Breast Cancer, Endocrine Therapy, Endocrine Therapy Adverse Reaction, Vitamin D Deficiency
- Trial name
- NUTRIBREAST (NCT04389424)
- Testing
- Tamoxifen, Exemestane, Anastrozole
- Where
- Mexico
- Volunteers
- 300 people
- Sponsor
- Instituto Jalisciense de Cancerologia
Diabetes Mellitus, Hepatitis C, Chronic
People With CHC Who Achieved a Sustained Virological Response Following Therapy With Direct Acting Antiviral Agents
Background: Chronic hepatitis C infects the liver. It may scar the liver. This is called cirrhosis and may lead to liver cancer or death. Current chronic hepatitis C treatments cure most people.
- Conditions
- Diabetes Mellitus, Hepatitis C, Chronic, Cardiovascular Diseases
- Trial name
- NCT03520660
- Testing
- Epclusa
- Where
- United States
- Volunteers
- 121 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Thyroid Cancer, Nonmedullary, Colon Carcinoma
Trained Immunity in Thyroid Carcinoma and Colon Carcinoma
Tumor-related inflammation is one of the hallmarks of cancers in general. Innate immunity specifically is a common denominator which is involved in the pathogenesis of both thyroid carcinoma and colon carcinoma.
- Trial name
- NCT05280379
- Testing
- no intervention will take place
- Where
- Netherlands
- Volunteers
- 33 people
- Sponsor
- Radboud University Medical Center
Cervical Cancer
Comparison of the Human Papillomavirus (HPV) Type 16 E7-Specific Immune Response Between a Normal Population and Patients With Cervical Lesions
Cervical cancer is the most frequent neoplasm and the third in mortality rate of the malignancies in women in the world. It results in about 200,000 women dying of cervical cancer each year worldwide.
- Trial name
- NCT00154583
- Where
- Taiwan
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- National Taiwan University Hospital
Polycystic Ovary Syndrome, Metformin
PCOS Immune Function Predicts Metformin Efficacy
In this study, the investigators will include PCOS patients who meet the trial criteria, introduce participants to the content of this study, and invite participants to participate.
- Conditions
- Polycystic Ovary Syndrome, Metformin, Immune Function
- Trial name
- NCT06325956
- Testing
- Metformin
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Shanghai 10th People's Hospital
Intracranial Germ Cell Tumor, Intracranial Germ Cell CNS Tumor, Childhood
Surveillance of Association of Immune Status and Prognosis of CNS Germ Cell Tumor Survivors
Platinum-based chemotherapy, alternating at 21-days intervals with cycles of ifosfamide, cisplatin, and etoposide (ICE) and subsequently received radiotherapy were considered as standard treatment for intracranial germ cell…
- Conditions
- Intracranial Germ Cell Tumor, Intracranial Germ Cell CNS Tumor, Childhood, Surgery
- Trial name
- NCT04909307
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Chengcheng Guo
Non-Small Cell Lung Cancer, Exercise Training
EXERCISE AND THE IMMUNE RESPONSE IN LUNG CANCER
This project is about the effect of a 12-week training therapy intervention in patients suffering from non-small cell and small-cell lung cancer.
- Conditions
- Non-Small Cell Lung Cancer, Exercise Training, Immunotherapy, Small Cell Cancer Of The Lung
- Trial name
- ImmuEX (NCT07267000)
- Testing
- Exercise, Control
- Where
- Austria
- Volunteers
- 50 people
- Sponsor
- Medical University of Graz
Colorectal Cancer, Colorectal Carcinoma
A Phase I/II Study of Pexa-Vec Oncolytic Virus in Combination With Immune Checkpoint Inhibition in Refractory Colorectal Cancer
Background: Immune-based approaches in colorectal cancer have unfortunately with the notable exception of immune checkpoint inhibition in microsatellite instable (MSI-hi) disease been largely unsuccessful.
- Conditions
- Colorectal Cancer, Colorectal Carcinoma, Colorectal Adenocarcinoma, Refractory Cancer
- Trial name
- NCT03206073
- Testing
- Durvalumab, Tremelimumab, Pexa-Vec
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- National Cancer Institute (NCI)
Metastatic Renal Cancer
Everolimus Modulation of Anti-tumor T CD4 Immune Responses
Everolimus is an inhibitor of mammalian target of rapamycin, approved in patients with metastatic renal cell carcinoma. The objective of this study is to investigated the influence of everolimus immune modulation on antitumor…
- Trial name
- EMIR (NCT02837757)
- Testing
- Biological samples
- Where
- 3 sites in France
- Volunteers
- 14 people
- Sponsor
- Centre Hospitalier Universitaire de Besancon